Alopecia Areata: Advances in Clinical Evaluation and Pathogenesis

Alopecia areata (AA) is a common autoimmune condition that affects approximately 2% of the global population. Although it most commonly presents with the abrupt onset of well-circumscribed, non-scarring alopecic patches on the scalp, the nails and other hair-bearing areas are also frequently affected. Clinical evaluation should document disease extent and employ trichoscopy to identify characteristic signs of the condition (e.g., black-dot hairs, exclamation point hairs). The Severity of Alopecia Tool (SALT) is standard for quantifying severity, and newer instruments like the Alopecia Areata Severity Scale (AASc) incorporate extra-scalp involvement and psychosocial burden. Moreover, machine learning approaches and validated patient-reported outcome measures, such as the Alopecia Areata Patient Priority Outcomes (AAPPO), have emerged that can standardize assessment and longitudinal tracking. AA prognosis is influenced by several factors, including age, disease subtype, extent and duration of hair loss, and family history. Pathogenesis is heterogeneous, multifactorial, and includes the collapse of immune privilege with cytotoxic CD8+ T cell inflammation. Genetic and pharmacologic data support a key role for the JAK/STAT pathway and demonstrate that Th2-related inflammation is involved in select patients. The quality-of-life impact of AA and associated comorbidities are substantial.